Moderna (MRNA) and Merck (MRK) vaccine succeeds in preventing Melanoma from returning, reports WSJ

Positive readouts from the personalised cancer vaccine programme, the mRNA neoantigen therapy paired with Keytruda, have followed a consistent pattern in this partnership: staged data from an early-phase melanoma adjuvant study, with each update moving the smaller partner's shares more violently than the larger one's, since the programme is a rounding error on Merck's Keytruda franchise but a core valuation pillar for Moderna in its post-Covid revenue gap. The distinction that matters is recurrence-free survival versus overall survival; the former is what these updates have reported, the latter is the harder endpoint regulators and payers ultimately price, and prior updates on this programme have drawn scrutiny over durability, control-arm crossover and biomarker-defined subgroups. The commercial channel runs through Merck's incentive to diversify Keytruda ahead of loss of exclusivity and Moderna's need to prove the platform beyond infectious disease, which is why both sponsors have historically paired data releases with capacity and pivotal-trial announcements. The follow-ons in episodes of this kind are the confirmatory late-stage study readouts, regulatory interactions on an accelerated pathway, and any overall-survival maturation. As trial data rather than an approval, the read-through is directional for the oncology-vaccine peer set.